Clinical trials: Glioma Tumor Recurrence
Brain and Central Nervous System Tumors
Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic Oligodendroglioma
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells, and may be an effective treatment for anaplastic oligodendroglioma. Combining combination chemotherapy with radiation therapy may kill more tumor cells.
- Trial name
- NCT00002840
- Testing
- lomustine, procarbazine hydrochloride, vincristine sulfate
- Where
- 40 sites in Austria, Belgium and 10 more
- Volunteers
- 350 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well palbociclib works in treating patients with Rb positive solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with activating alterations (mutations) in cell cycle genes…
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma
- Trial name
- NCT03526250
- Testing
- Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study
- Where
- 117 sites in United States, Puerto Rico
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as thrombopoietin and G-CSF may increase the number of immune cells found in…
- Trial name
- NCT00003597
- Testing
- recombinant human thrombopoietin, carboplatin, etoposide
- Where
- 24 sites in United States, Australia
- Volunteers
- 16 people
- Sponsor
- Children's Oncology Group
Recurrent High Grade Gliomas
Protocol to Distinguish Tumor Recurrence From Treatment-Related Necrosis in Patients With High Grade Gliomas
Brain imaging tests are routinely used to detect the presence of a brain tumor or to evaluate the response to treatment. Sometimes the images obtained are not specific and the only way to establish a diagnosis is by obtaining a…
- Trial name
- NCT00942760
- Testing
- 3T MRI
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Glioblastoma
A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma.
Phase I/II clinical trial on the per-operative intra-tumoral administration of myeloid dendritic cells plus ipilimumab and nivolumab, followed by repeated intracavitary administration of ipilimumab and nivolumab plus intravenous…
- Trial name
- GlitIpNi (NCT03233152)
- Testing
- Ipilimumab (YervoyTM, 50 mg/10 mL solution), Nivolumab (OpdivoTM, 40 mg/4mL solution), Autologous CD1c(BDCA-1)+ /CD141(BDCA-3)+ myDC
- Where
- Belgium
- Volunteers
- 110 people
- Sponsor
- Universitair Ziekenhuis Brussel
Glioma
Phase 2 Study of Vinblastine in Children With Recurrent or Refractory Low Grade Glioma
This study is examining whether Vinblastine is an effective drug to shrink low grade glioma brain tumors in children, and what the side effects are.
- Trial name
- NCT00213278
- Testing
- vinblastine sulphate injection
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- The Hospital for Sick Children
Glioblastoma
Exploratory Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247, Beijing YSCell Biotech Co., Ltd. [Abbreviated as YS])in Patients With Recurrent or Progressive Glioblastoma
This is a single-center, open-label, dose-escalation, multiple-dose investigator-initiated trial (IIT). The trial aims to evaluate the safety and tolerability of autologous dendritic cell injection sensitized with tumor…
- Trial name
- NCT07678138
- Testing
- Neoantigen DC Vaccine (YS247) for Glioblastoma
- Volunteers
- 9 people
- Sponsor
- Huanhu Hospital Affiliated to Tianjin Medical University
Recurrent Malignant Glioma
Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients
This is an open label Phase 1b clinical trial of IV administration of OKN-007 in a pilot cohort of human recurrent malignant glioma patients.
- Trial name
- OKN-007 (NCT01672463)
- Testing
- OKN-007
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Oblato, Inc.
Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas
Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas
This is a multicenter, safety and pharmacokinetic trial to determine the MTD and/or select a recommended phase 2 dose (RP2D) of vemurafenib in children with recurrent or refractory gliomas containing the BRAFV600E or BRAF Ins T…
- Trial name
- NCT01748149
- Testing
- Vemurafenib
- Where
- 21 sites in United States, Canada
- Volunteers
- 40 people
- Sponsor
- University of California, San Francisco
Recurrent Glioblastoma, Gliosarcoma
Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma
This is a study to determine the efficacy, safety and clinical benefit (how well the drugs works), of the pharmaceutical compositions in Nasal Spray NST-4G for the treatment of brain tumors( Recurrent Glioblastoma…
- Conditions
- Recurrent Glioblastoma, Gliosarcoma, Anaplastic Gliomas
- Trial name
- NCT03275558
- Testing
- Axitinib 1 MG, Sunitinib 5 MG, Pazopanib 5 MG
- Where
- 2 sites in Hong Kong, Singapore
- Sponsor
- Center Trials & Treatment
Ependymoma
Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod
The purpose of this study is to see if vaccination with HLA-A2 restricted peptides, combined with the immunoadjuvant imiquimod is safe and can induce immune responses in children with recurrent ependymomas.
- Trial name
- NCT01795313
- Testing
- HLA-A2 restricted synthetic tumor antigen, Imiquimod, enzyme-linked immunosorbent assay
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- James Felker
Glioma
Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas
The purpose of this study is to determine the survival, disease response, and side effects of Tasigna® (nilotinib) in patients who have malignant gliomas and are positive for Platelet Derived Growth Factor Receptor (PDGFR)…
- Trial name
- NCT01140568
- Testing
- nilotinib
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- David Piccioni, M.D., Ph.D
HIGH GRADE GLIOMA
Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab
The Primary Objectives are: To determine the extent by which TH-302 is able to penetrate the blood brain barrier and affect tumor tissue To assess the safety of single dose TH-302 in patients with high grade glioma undergoing…
- Trial name
- NCT01403610
- Testing
- TH-302 preoperative, TH-302 (escalating) with bevacizumab 10mg/kg
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Glioblastoma, Glioblastoma Multiforme
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
This is an open-label, multi-center Phase 0 study with an expansion phase that will enroll up to 24 participants with newly-diagnosed glioblastoma and up to 18 recurrent glioma participants with IDH mutation and ATRX loss.
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Glioma, GBM
- Trial name
- NCT05076513
- Testing
- Niraparib, Radiation therapy
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Nader Sanai
Glioblastoma
A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
This multicenter, Phase 1b/2 study is being conducted to determine if the experimental cell therapy is safe, tolerable and can delay the return of cancer in patients with a newly diagnosed or recurrent glioblastoma multiforme…
- Trial name
- NCT05664243
- Testing
- Autologous genetically modified gamma-delta T cells, Allogeneic genetically modified gamma-delta T cells
- Where
- 5 sites in United States
- Volunteers
- 4 people
- Sponsor
- In8bio Inc.
Malignant Glioma, Recurrent Glioma
Personalized Vaccine for Patients With Recurrent Malignant Glioma
A single-arm, single-center, open-labeled study will be conducted with an aim to investigate the feasibility, safety, and efficacy of the personalized vaccine for patients with recurrent malignant glioma.
- Trial name
- NCT04943718
- Testing
- personalized vaccine
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Xuanwu Hospital, Beijing
Medulloblastoma Recurrent, Ependymoma Recurrent
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
Patients with with recurrent or progressive medulloblastoma, ependymoma, atypical teratoid rhabdoid tumor (ATRT), and CNS tumors of various histologies have a very poor prognosis whether treated with conventional chemotherapy…
- Conditions
- Medulloblastoma Recurrent, Ependymoma Recurrent, ATRT Recurrent, Rare CNS Tumor Recurrent
- Trial name
- MEMMAT (NCT01356290)
- Testing
- Bevacizumab, Thalidomide, Celecoxib
- Where
- 22 sites in United States, Austria and 6 more
- Volunteers
- 232 people
- Sponsor
- Medical University of Vienna
Brain and Central Nervous System Tumors
COL-3 in Treating Patients With Progressive or Recurrent Brain Tumors
RATIONALE: COL-3 may stop the growth of brain tumors by stopping blood flow to the tumor. PURPOSE: Phase I/II trial to study the effectiveness of COL-3 in treating patients who have progressive or recurrent brain tumors following…
- Trial name
- NCT00004147
- Testing
- incyclinide
- Where
- 9 sites in United States
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium
Glioblastoma, Brain Neoplasm
Bevacizumab With or Without Surgery for Adult Glioblastomas
Background: Glioblastoma (GBM) is the most common malignant brain tumor in adults. Patients with GBM are usually treated with surgery, radiation, and chemotherapy. Despite this treatment, most GBMs start growing again.
- Trial name
- NCT01413438
- Testing
- Craniotomy
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Glioblastoma
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination with Standard of Care and in Recurrent Glioblastoma as a Single Agent
- Trial name
- NCT05109728
- Testing
- [177Lu]Lu-DOTA-TATE, [68Ga]Ga-DOTA-TATE, Temozolomide
- Where
- 14 sites in United States, France and 3 more
- Volunteers
- 63 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.